Millions of people who use popular weight-loss injections like Ozempic and Wegovy have one major concern: if they stop taking the medication, the weight they lost will swiftly return. However, a large real-world study from the Cleveland Clinic now reveals that this widely held concern may be exaggerated, with many patients managing to maintain their weight even after discontinuing the medications. 

The study, published in the journal Diabetes, Obesity, and Metabolism, examined the treatment paths of over 8,000 persons who had begun taking the injectable medications semaglutide and tirzepatide. These pharmaceuticals are classified as GLP-1 medications, which help manage hunger and blood sugar by telling the brain that the stomach is full and slowing digestion. 

Scientists investigated what happened when patients stopped using the medicine within three to twelve months of starting treatment. Unlike previous scientific trials, which revealed that patients could regain more than half of their lost weight within a year of ceasing the injections, the real-world data are more comforting. 

The Cleveland Clinic team, coordinated by Hamlet Gasoyan, DS, PhD, MPH, of the institution's Center for Value-Based Care Research, followed 7,938 patients in Ohio and Florida who were given the injections for obesity or type 2 diabetes. The researchers next tracked how individuals' weight fluctuated over the course of a year after discontinuing treatment. 

The study discovered that participants treated for obesity dropped an average of 8.4 per cent of their body weight before discontinuing the drug. One year later, they had only recovered about 0.5% on average. The findings were even more remarkable among diabetics, who dropped an average of 4.4 per cent before discontinuing the medicines and an additional 1.3 per cent over the next year. 

Although weight reductions varied by person, a considerable proportion of patients were able to stabilise or continue to lose weight. In the obese group, 45 per cent continued to lose or maintain their weight a year after discontinuing treatment. In the diabetic group, the proportion increased to 56%. 

"Our real-world data show that many patients who stop semaglutide or tirzepatide restart the medication or transition to another obesity treatment, which may explain why they regain less weight than patients in randomised trials," according to Dr Gasoyan. 

Researchers claim the findings represent how people act outside of tightly controlled clinical studies. When patients discontinue current GLP-1 injections, frequently due to high costs, restricted insurance coverage, or adverse effects, many swiftly transition to alternative tactics rather than discontinuing treatment entirely. 

The study discovered that approximately 27% moved to another medicine, such as older obesity treatments or a different GLP-1 therapy. Around 20% eventually resumed the original medicine, while 14% continued their therapy through lifestyle changes such as consultations with dietitians or fitness professionals. Less than 1% selected metabolic or bariatric surgery. 

Cost surfaced as the primary reason many patients stopped receiving injections. These medications can cost more than $1,000 per month without insurance, making long-term therapy challenging for many families. 

Nonetheless, the study demonstrates that discontinuing injections does not always imply a loss of development. Many individuals appear to adapt by combining medical guidance, alternative medications, and lifestyle adjustments to maintain their weight reduction gains, such as engaging in regular physical activity and following a balanced diet. 

"Many patients do not give up on their obesity treatment journey, even if they need to stop their initial medication," the doctor stated. "In our future work, we will examine the comparative effectiveness of alternative treatment options for obesity in patients who discontinue semaglutide or tirzepatide to help patients and their clinicians make informed decisions." 

According to public health specialists, the findings emphasise the significance of ongoing medical care in obesity treatment. Rather than relying solely on a single prescription, successful long-term weight management frequently requires a combination of medications, nutritional guidance, and continuous lifestyle modifications.